

Editorial on Nipah Virus: A Looming Threat

Ambadasu Bharatha

Lecturer in Pharmacology, Faculty of Medical Sciences,
The University of the West Indies, Cave Hill Campus,
Barbados

*Kandamaran Krishnamurthy**

Senior Associate Lecturer in Pediatrics, Faculty of Medical
Sciences, The University of the West Indies, Cave Hill
Campus, Barbados

**Corresponding Author*

Introduction

Nipah virus (NiV) is a highly pathogenic paramyxovirus that emerged in the late 20th century, causing severe disease in humans and animals. It was first detected during outbreaks in Malaysia and Singapore in 1999, mainly affecting pig farmers and people in close contact with pigs (1). Sungai, Malaysia. The virus is named after the village of Nipah, where the first coronavirus case was reported. A recent outbreak was observed in Kerala, India, the fourth outbreak in the region in five years, primarily caused by fruit flies, with mortality rates ranging from 40% to 75% and varying in disease status (2).

Characteristics and Reservoir

NiV is characterized by high virulence and high mortality rates in humans, ranging from 40% to 75% depending on the strain and strain (1). The natural reservoir of NiV is in fruit bats of the family *Pteropodidae*, especially *Pteropus* bats found in many areas (3). Managing wildlife and improving bat habitats have been suggested as measures to control the spread of the virus, as the virus can be spread by acquired animals, the disease or by contact with human body fluids (2).

Molecular Aspects of NiV

A recent article by Skowron et al. provides insight into the molecular components of NiV, focusing on its structure, morphology, and entry into recipient cells. NiV is an enveloped, negative-sense, single-stranded RNA virus from the genus *Henipavirus*. The virus uses its G glycoprotein to attach to ephrin-B2 and ephrin-B3 receptors on host cells, facilitating entry and subsequent entry. Understanding the molecular mechanisms of NiV is critical and effective treatments and vaccines emphasize the importance of drugs (4).

Epidemiological Insights

An article by Joshi et al. provides insights into the epidemiological components of NiV and its impact on public health. It discusses the diverse outbreaks of NiV, emphasizing the need for enhanced surveillance and early detection to control its unfolding. The article additionally highlights the function of ecological changes and human sports in the emergence and re-emergence of NiV, declaring the significance of addressing environmental and ecological factors in dealing with NiV outbreaks (5).

Transmission Dynamics

NiV is primarily through direct contact with infected animals or consumption of food contaminated with the virus (6). This strain in India and Bangladesh is different and more deadly than the one in Malaysia two decades ago. It can cause infection, emphasizing the need for a strong control program prevention in these areas (2).

Scientific Advances in Nipah Virus Research

Scientific advancements in NiV research have been substantial, encompassing a broad spectrum of areas, including epidemiology, biology, diagnostics, therapeutics, and vaccine development (1). The exploration of potential antiviral drugs targeting the viral entry process is a promising strategy to combat NiV infections. The synergy achieved through multidisciplinary approaches and international collaborations has accelerated advancements in NiV research, fostering the development of comprehensive strategies to combat this virus (4).

Vaccines and Antivirals for Nipah Virus

The pursuit of vaccines and antivirals for NiV is driven by its high mortality rate and the capability for widespread transmission (7). There are presently no approved vaccines or treatments, but studies are ongoing, with several promising applicants undergoing medical assessment. The improvement of effective vaccines and antivirals is paramount for managing NiV infections and decreasing associated mortality rates, however, the journey is fraught with challenges, together with the variety of virus strains and the need for a deeper understanding of the immune reaction to NiV contamination (2).

Knowledge Gaps and Challenges in Nipah Virus Research

Addressing knowledge gaps and challenges in NiV research is important for effective intervention planning and prevention strategies. Significant knowledge gaps exist in understanding viral diversity, animal vectors, human disease incidence, and the role of environmental factors in the emergence and spread of NiV. These gaps hamper the use of vaccines to promote effective protection and therapeutic intervention. Challenges in NiV research include lack of rapid diagnosis, limited treatment uptake, difficulty in developing vaccines due to heterogeneous virus strains, resources used in affected areas, and the need for public awareness and education (8).

Future Directions

Addressing existing knowledge gaps is essential to develop more effective preventive treatment strategies. International cooperation should be strengthened to enhance research, investigation and response to emerging NiV and similar viruses. Clinical trials for potential vaccines and antiviral drugs should be accelerated, and strategies should be implemented to ensure the availability of these treatments.

References

1. Arunkumar G, Chandni R, Mourya DT, Singh SK, Sadanandan R, Sudan P, et al. Outbreak Investigation of Nipah Virus Disease in Kerala, India, 2018. *J Infect Dis*. 2019;219(12):1867-78.
2. Conroy G. Nipah virus outbreak: what scientists know so far. *Nature*. 2023.
3. Luby SP, Gurley ES, Hossain MJ. Transmission of human infection with Nipah virus. *Clin Infect Dis*. 2009;49(11):1743-8.
4. Skowron K, Bauza-Kaszewska J, Grudlewska-Buda K, Wiktorczyk-Kapischke N, Zacharski M, Bernaciak Z, et al. Nipah Virus-Another Threat From the World of Zoonotic Viruses. *Front Microbiol*. 2021;12:811157.
5. Joshi J, Shah Y, Pandey K, Ojha RP, Joshi CR, Bhatt LR, et al. Possible high risk of transmission of the Nipah virus in South and South East Asia: a review. *Trop Med Health*. 2023;51(1):44.
6. Clayton BA. Nipah virus: transmission of a zoonotic paramyxovirus. *Curr Opin Virol*. 2017;22:97-104.
7. Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. *Vaccine*. 2011;29(34):5623-30.
8. Broder CC, Weir DL, Reid PA. Hendra virus and Nipah virus animal vaccines. *Vaccine*. 2016;34(30):3525-34.